Kite, Arcellx to Co-develop and Co-commercialize CART-ddBCMA in Multiple Myeloma

  Kite Pharma, a Gilead Company (NASDAQ: GILD), and Arcellx Inc.,  (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.

Currently being investigated in a Phase 2 pivotal trial, CART-ddBCMA is Arcellx’s T-cell therapy utilizing the company’s novel synthetic binder, the D-Domain. Kite and Arcellx will jointly advance and commercialize the CART-ddBCMA asset in the U.S., and Kite will commercialize the product outside the U.S.

https://www.biospace.com/article/releases/kite-and-arcellx-close-agreement-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma/